Breaking News

TAG: US FDA

Alzheimer’s drug no cash cow

by Max Nisen The U.S. Food and Drug Administration’s approval last week of Biogen Inc.’s Alzheimer’s treatment aducanumab was a mistake based on weak evidence. The question now is just how much the U.S. will spend on a drug that may not help patients. No one but Biogen will like the ...